SRPT

SEC Filing Summary: AVI BioPharma, Inc. (10-Q)

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for AVI BioPharma, Inc. for the period ended March 31, 2009. The company is a development-stage biopharmaceutical firm focused on antisense therapeutics, particularly for viral hemorrhagic fevers (Ebola, Marburg) and genetic disorders. The filing notes that the company has incurred losses since its inception in 1980 and has no material revenue from product sales.

Key Financial Metrics

Operating Expenses: Total operating expenses were $6.72 million for Q1 2009, down significantly from $19.37 million in Q1 2008. This decrease is largely due to the absence of a $9.92 million charge for acquired in-process research and development (IPR&D) recorded in Q1 2008 related to the Ercole Biotechnology acquisition.

Material Changes vs. Prior Period

• Revenue Decline: Revenues decreased by approximately 44% compared to Q1 2008, driven by a reduction in recognized revenue from government research contracts.
• Expense Reduction: Operating expenses dropped by roughly 65% year-over-year. The primary driver was the non-recurring $10 million IPR&D charge in the prior year. Excluding that charge, R&D and G&A expenses also saw modest declines.
• Warrant Liability Gain: The company recorded a $2.62 million gain on warrant liability in Q1 2009, compared to a $1.44 million loss in Q1 2008. This gain resulted from a decline in the company's stock price following a January 2009 equity financing, which reduced the fair value of warrants classified as liabilities.
• Liquidity Improvement: Cash and cash equivalents increased by $13.5 million to $24.7 million, primarily due to net proceeds of $15.5 million from a registered equity financing in January 2009.

Guidance, Outlook, and Risks

Outlook and Guidance: Management expects expenditures for 2009, net of government funding, to be approximately $10 to $12 million. The company believes it has sufficient cash to fund operations for at least the next 12 months, excluding future receipts from existing government contracts. The company anticipates receiving additional government funding for antiviral development in 2009.

Risks and Contingencies:

• Capital Needs: The company has an accumulated deficit of $251.2 million and expects to continue incurring losses. Future financing is required to sustain operations beyond the next 12 months.
• Government Contract Reliance: A significant portion of revenue relies on U.S. government contracts (e.g., DTRA). Termination or delay of these contracts due to funding issues or performance could materially impact financial condition.
• Regulatory Approval: Products are in early clinical stages. There is no assurance of FDA approval, particularly for products relying on the "Animal Rule" pathway for Ebola and Marburg treatments.
• Stock Listing: The company's stock price has fallen below the $1.00 minimum bid price required for NASDAQ Global Market listing. While enforcement is suspended until July 2009, failure to maintain compliance could result in delisting.
• Intellectual Property: The company faces potential patent infringement claims regarding its drug candidate AVI-4658, though it intends to defend against such claims.

Investor Verification Checklist

• Verify the status and funding timeline of the $28 million DTRA contract and the $11 million Defense Appropriations Act allocation.
• Confirm the company's ability to maintain NASDAQ listing compliance given the stock price volatility and minimum bid price requirements.
• Review the details of the January 2009 equity financing and the terms of the warrants issued, which are classified as liabilities and impact net income volatility.
• Assess the progress of clinical trials for lead candidates (e.g., AVI-4658 for Duchenne muscular dystrophy) and the timeline for potential regulatory filings.
• Monitor the company's cash burn rate against the projected $10-$12 million operating expenditure for 2009.